Calliditas Therapeutics announces full FDA approval of TARPEYO®
On December 20, 2023, TARPEYO received full FDA approval for the new indication to reduce the loss of kidney function in adults with IgA Nephropathy (IgAN) who are at risk …
Subscribe to our newsletter below!